Literature DB >> 28577657

Oral lesions associated with Fanconi anemia.

Eric T Stoopler1, Lujain Homeida2, Thomas P Sollecito2.   

Abstract

Entities:  

Year:  2017        PMID: 28577657      PMCID: PMC5457467          DOI: 10.1016/j.bjhh.2017.03.003

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


× No keyword cloud information.
A middle-aged man complained of symptomatic oral lesions. Family history was positive for Fanconi anemia (FA). An intraoral examination revealed generalized erythroleukoplakia with focal ulcerations affecting the palate (Figure 1). Differential diagnosis included lichenoid lesions, dysplasia and squamous cell carcinoma (SCC). Previous biopsies demonstrated mild to moderate dysplasia. The patient underwent genetic testing and was diagnosed with FA.
Figure 1

Generalized erythroleukoplakia with focal ulcerations affecting the hard and soft palate.

Generalized erythroleukoplakia with focal ulcerations affecting the hard and soft palate. FA is an autosomal recessive disorder characterized by physical abnormalities, bone marrow failure and predisposition to hematologic and solid malignancies. Oral findings associated with FA include mucosal lesions, periodontal disease and dental anomalies. FA patients are considered high-risk for oral SCC.

Conflicts of interest

The authors declare no conflicts of interest.
  3 in total

Review 1.  Fanconi Anemia: Overview of the Disease and the Role of Hematopoietic Transplantation.

Authors:  Alexandra Schifferli; Thomas Kühne
Journal:  J Pediatr Hematol Oncol       Date:  2015-07       Impact factor: 1.289

2.  Dental Perspective of Rare Disease of Fanconi Anemia: Case Report with Review.

Authors:  Mridula Goswami; Urvashi Bhushan; Manoj Goswami
Journal:  Clin Med Insights Case Rep       Date:  2016-03-17

3.  Fanconi anemia: young patients at high risk for squamous cell carcinoma.

Authors:  Eunike Velleuer; Ralf Dietrich
Journal:  Mol Cell Pediatr       Date:  2014-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.